DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Gaudium IVF Q1 FY27 Results: Revenue Rises 9.1% YoY to ₹19.38 Cr

Trade Brains 4 hrs ago·14 Aug 2026, 7:30 am

Gaudium IVF has released its Q1 FY27 results, showing a 9.1% year-over-year increase in revenue. This growth indicates a positive start to the fiscal year for the company.

The company's expansion strategy, including new hubs and AI-led fertility solutions, is driving up costs. This increase in spending has led to a weakening in reported profitability.

Investors will be watching to see if Gaudium IVF's aggressive growth strategy pays off in the long run, and if the company can balance its spending with revenue growth.